| scholarly article | Q13442814 |
| P2093 | author name string | I Ahmad | |
| A Ahmad | |||
| R Patel | |||
| M S Reddy | |||
| S Sheikh | |||
| T Shah | |||
| K K Verma | |||
| B B Chandrakant | |||
| Bsv Prasad | |||
| H Barkate | |||
| M Paithankar | |||
| P Kale | |||
| R V Solanki | |||
| P2860 | cites work | Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial | Q50246045 |
| Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma | Q57072034 | ||
| Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication | Q22253031 | ||
| Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study | Q28248076 | ||
| Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group | Q28375949 | ||
| Protein kinase C inhibition rescues manic-like behaviors and hippocampal cell proliferation deficits in the sleep deprivation model of mania. | Q30630808 | ||
| Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative | Q34026000 | ||
| Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects | Q34146176 | ||
| Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies | Q34558705 | ||
| Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen | Q34757926 | ||
| The armamentarium of treatments for bipolar disorder: a review of the literature | Q36687093 | ||
| A role for the PKC signaling system in the pathophysiology and treatment of mood disorders: involvement of a functional imbalance? | Q37943726 | ||
| Endoxifen is a new potent inhibitor of PKC: a potential therapeutic agent for bipolar disorder | Q43130427 | ||
| Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group | Q43507067 | ||
| Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy | Q43846648 | ||
| Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial | Q44299951 | ||
| A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
| Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study | Q44874572 | ||
| Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial | Q44915194 | ||
| Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol | Q45168624 | ||
| Risperidone in the treatment of acute mania: double-blind, placebo-controlled study | Q46681460 | ||
| Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: A randomized, placebo-controlled study | Q48336807 | ||
| Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study | Q48407645 | ||
| P407 | language of work or name | English | Q1860 |
| P577 | publication date | 2016-06-27 | |
| P1433 | published in | Clinical and Translational Science | Q5133809 |
| P1476 | title | Endoxifen, a New Treatment Option for Mania: A Double-Blind, Active-Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen |
Search more.